Cartalax, BPC-157, TB-500 & KPV Blend is cataloged as a multi-component research product. The site's structured catalog data lists four components: Cartalax, BPC-157, TB-500, and KPV. The combination has not been established as a single pharmacologic entity; component identity, purity, and interactions should be confirmed against the supplier's certificate of analysis before laboratory use.
BPC-157 has been investigated mainly in preclinical systems, including work connecting it with VEGFR2-Akt-eNOS signaling; its molecular target is not established. TB-500 is often described as thymosin-beta-4-derived, but the term does not by itself establish an exact sequence — native thymosin beta-4 binds and sequesters monomeric actin, and applying that mechanism to the catalog material requires identity verification. KPV is the C-terminal tripeptide of alpha-MSH and has been studied in cell and animal models involving NF-kappaB and other inflammatory-signaling pathways; its direct target and behavior in this blend remain uncertain. Cartalax is documented by vendors as the synthetic tripeptide Ala-Glu-Asp (AED), CAS 160450-67-3; no primary-literature (PubMed) records for Cartalax were found, so no receptor or signaling mechanism can be assigned, and vendor-documented identity is not a substitute for lot-specific certificate-of-analysis verification. No established mechanism of action exists for the combined formulation; the component notes must not be interpreted as evidence of additive or synergistic activity.